The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Figure 1: Neurotrophins bind to and stimulate the activity of their receptors, the Trk tyrosine ... PI-3 kinase. Thus, NT3 potentiates release by activating both PI-3 kinase and PLC-γ pathways ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors ... with these pathways can suppress ...

DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in ...

The VEGF (vascular endothelial growth factor) pathway has emerged as an important target ... of various VEGFRs (VEGF receptors), which are a part of the receptor tyrosine kinase superfamily. VEGFR1 ...

Enzyme kinetic data from the BRENDA database were mapped onto the genome-scale metabolic model of Saccharomyces cerevisiae to ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...